VNDA

Rating neutralTentativeAI Memo

Vanda

As of 2026-10-22/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-10-22 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

Quimilza FDA decision • 2026-12-12

Base target: $4 / p=45% prob

Biggest risk

The October 14 Phase III VQW-765 study missed both its primary and key secondary endpoints, and Vanda placed the social-anxiety program on hold pending full-data analysis. That removes a previously anticipated 2026 readout from the upside case. Vanda release.

Invalidation

Break below $3 or thesis failure.

What would change my mind?

Fanapt Q2 sales rose 23% year over year to $36.0 million, while Vanda reported $170.0 million of June-end cash and expected funding through at least 2027. Quimilza approval, a positive NEREUS readout, or progress toward a HETLIOZ sNDA could support upside. [#SEC-8K-2026-08-05] SEC-filed company release.

Research note

Recommendation

neutral

Confidence

medium

As of

2026-10-22

Base target

p=45%

Bull target

p=25%

Bear target

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

HETLIOZ supplemental-application path
Fanapt Q2 sales rose 23% year over year to $36.0 million, while Vanda reported $170.0 million of June-end cash and expected funding through at least 2027.
Quimilza approval, a positive NEREUS readout, or progress toward a HETLIOZ sNDA could support upside.

BearKey bullets

Q2 total net product sales declined 4% year over year despite Fanapt growth; launch spending and the expected later expense moderation remain execution risks.
[#SEC-8K-2026-08-05].
Quimilza could receive an FDA delay or rejection on its December 12 target date.

WatchKey bullets

Quimilza FDA decision

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $4 (p=45%)

Target spread vs base: +36% / -43%

Scenario probabilities

Bull Target: $6 (p=25%)Base Target: $4 (p=45%)Bear Target: $3 (p=30%)

Commentary

The positive September HETLIOZ result was followed by the October 14 VQW-765 failure, a material deterioration from the prior speculative-buy thesis. Reuters reported shares down about 17% in extended trading immediately after the failure; the packet's later October 21 anchor is $4.01. Reuters. No verified post-print analyst revisions, options skew, short-interest, employee score, or sufficient social measure were available; zero-valued fields denote missing data, not neutral readings. The deterministic prior remains positive, but the failed trial and thin target coverage limit conviction.

As of 2026-10-22 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

HETLIOZ supplemental-application path

Scenarios

Bull Target (Scenario probability)

$6 / p=25% prob

Base Target (Scenario probability)

$4 / p=45% prob

Bear Target (Scenario probability)

$3 / p=30% prob

Analysis 2026-10-22 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

-0.40

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-12-12
Quimilza FDA decision
The FDA target action date for Quimilza in generalized pustular psoriasis is December 12, 2026. Approval, delay, or rejection could materially change the pipeline valuation. [#SEC-8K-2026-08-05] SEC-filed company release.
Prob 50.00% • Move 20.00% • Priced-in 45.00%
EVENT2026-12-31
NEREUS GLP-1 vomiting trial readout
Vanda expected results from its Phase III NEREUS study in patients receiving GLP-1 therapies during 2026. The outcome remains unreported in the checked evidence; the date is a company-stated window, not a confirmed release date. [#SEC-8K-2026-08-05] SEC-filed company release.
Prob 60.00% • Move 15.00% • Priced-in 30.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

HETLIOZ supplemental-application path
2027-06-30
Vanda reported a 37.1-minute placebo-adjusted improvement in sleep-onset timing in its Phase III delayed sleep-wake phase disorder study and intends to discuss the data with FDA and submit an sNDA. The analyzed primary-endpoint groups had 20 participants each; no filing date or approval is assured. [#PR-EARNINGS-2026-09-29].
Prob 60% • Move 12% • Priced-in 55%

Risks

Q2 total net product sales declined 4% year over year despite Fanapt growth; launch spending and the expected later expense moderation remain execution risks. [#SEC-8K-2026-08-05].
Quimilza could receive an FDA delay or rejection on its December 12 target date. [#SEC-8K-2026-08-05].
The HETLIOZ sleep-disorder trial analyzed only 20 patients per arm on its primary endpoint, and an sNDA has not yet been filed. [#PR-EARNINGS-2026-09-29].
VQW-765 showed virtually no separation from placebo on its primary endpoint (65.6 versus 66.0; p=0.8899), and the program is on hold. Vanda release.
Vanda cautioned that anticipated developments may not be realized or have their expected effects. [#8-K-2026-08-05].

Peers

Symbol	Summary
ACAD	Commercial CNS-drug comparator for launch execution, but its larger revenue base and different indications make its valuation multiple a poor direct benchmark for VNDA.
SUPN	Marketed neurology and psychiatry medicines provide operating context, but its broader portfolio and different scale limit valuation comparability.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-10-22

Loading AI feed…

Symbol

Summary

ACAD

Commercial CNS-drug comparator for launch execution, but its larger revenue base and different indications make its valuation multiple a poor direct benchmark for VNDA.

SUPN

Marketed neurology and psychiatry medicines provide operating context, but its broader portfolio and different scale limit valuation comparability.